Deutsche Bank Ag\ Xtl Biopharmaceuticals LTD Transaction History

Deutsche Bank Ag\

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2019 May 15, 2019	SELL	$1.72 - $2.61 $2,236 - $3,393	-1,300 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$1.43 - $2.98 $1,859 - $3,874	1,300 New	1,300 $2,000

452K

Ticker XTLB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 5,449,060
Market Cap $13.9M
Description
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Ye...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.